(Q37849858)

English

Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 August 2017

Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection (English)

1 reference

Europe PubMed Central

24 August 2017

0 references

1 reference

based on heuristic

inferred from title

Chlamydia muridarum

object named as

Chlamydia muridarum

1 reference

based on heuristic

inferred from title

Scott A Halperin

9

object named as

Scott A Halperin

1 reference

Europe PubMed Central

24 August 2017

Robert E. W. Hancock

7

object named as

Robert E W Hancock

1 reference

Europe PubMed Central

24 August 2017

author name string

Tyler H T Brown

1

1 reference

Europe PubMed Central

24 August 2017

Jason David

2

1 reference

Europe PubMed Central

24 August 2017

Elizabeth Acosta-Ramirez

3

1 reference

Europe PubMed Central

24 August 2017

Jessica M Moore

4

1 reference

Europe PubMed Central

24 August 2017

Song Lee

5

1 reference

Europe PubMed Central

24 August 2017

Guangming Zhong

6

1 reference

Europe PubMed Central

24 August 2017

Zhou Xing

8

1 reference

Europe PubMed Central

24 August 2017

Jun Wang

10

1 reference

Europe PubMed Central

24 August 2017

language of work or name

0 references

publication date

8 November 2011

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

24 August 2017

30

1 reference

Europe PubMed Central

24 August 2017

2

1 reference

Europe PubMed Central

24 August 2017

350-360

1 reference

Europe PubMed Central

24 August 2017

Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Summary: The natural history and immunobiology of Chlamydia trachomatis genital infection and implications for Chlamydia control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

T cell responses in the absence of IFN-gamma exacerbate uterine infection with Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Critical role of the interleukin-17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with Chlamydia species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

IL-17/Th17 promotes type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Differences in innate immune responses correlate with differences in murine susceptibility to Chlamydia muridarum pulmonary infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Production of adenovirus vectors and their use as a delivery system for influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Prime-boost vectored malaria vaccines: progress and prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Genetic immunization in the lung induces potent local and systemic immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Tuberculosis vaccines: the past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Intranasal immunization promotes th17 immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Synthetic innate defence regulator peptide enhances in vivo immunostimulatory effects of CpG-ODN in newborn piglets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Characterization of a secreted Chlamydia protease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

TH17 cells in development: an updated view of their molecular identity and genetic programming

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Development in motion: helper T cells at work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

A protective function for interleukin 17A in T cell-mediated intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

Role of gamma interferon in controlling murine chlamydial genital tract infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

based on heuristic

inferred from DOI database lookup

Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.086

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.10.086

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37849858&oldid=2088594005"